Guggenheim Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Guggenheim Capital’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-46,157	Closed	-$1.12M	–	2904
2017 Q1	$1.12M	Buy	46,157 +9,832	+27%	+$246K	﹤0.01%	2048
2016 Q4	$1.17M	Buy	+36,325	New	+$1.55M	﹤0.01%	2061
2016 Q3	–	Sell	-53,519	Closed	-$2.27M	–	2949
2016 Q2	$2.27M	Buy	53,519 +174	+0.3%	+$9.48K	0.01%	1485
2016 Q1	$3.51M	Sell	53,345 -987	-2%	-$51.5K	0.01%	1191
2015 Q4	$3.38M	Sell	54,332 -6,211	-10%	-$437K	0.01%	1247
2015 Q3	$4.05M	Sell	60,543 -2,716	-4%	-$222K	0.01%	1147
2015 Q2	$6.16M	Buy	63,259 +10,110	+19%	+$962K	0.02%	1060
2015 Q1	$4.97M	Buy	53,149 +10,015	+23%	+$852K	0.01%	1166
2014 Q4	$3.83M	Buy	+43,134	New	+$3.14M	0.01%	1276

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Guggenheim Capital's MACK Position: Q2 2017 in Review

Guggenheim Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 46,157 shares — an estimated $1.12M sold.

Guggenheim Capital first reported a position in MACK in Q4 2014 and held it in 9 quarters. The position peaked at $6.16M in Q2 2015. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

Guggenheim Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Guggenheim Capital sold 46,157 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.12M.
Guggenheim Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
Guggenheim Capital's Merrimack Pharmaceuticals, Inc. position peaked at $6.16M in Q2 2015.
119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on Guggenheim Capital's 13F filing for Q2 2017, filed 14 Aug 2017.